New Clinical Outcome Measures to Remotely Evaluate Patients With FacioScapuloHumeral Muscular Dystrophy

You may be eligible if

• Genetically confirmed FSHD1 or clinical diagnosis of FSHD with characteristic findings on exam and an affected parent or offspring (40)
• Age 18-75 years
• Symptomatic limb weakness
• Patient able to walk alone or with a walking aid.
• Patient affiliated to the social security system
• Patient giving written consent after written and oral information.
• If taking over the counter supplements willing to remain consistent with supplement regimen throughout the course of the study
• Patients with comorbidity not related to the disease that can modify the natural evolution of the disease or would interfere with safe testing in the opinion of the Investigator
• Regular use of available muscle anabolic/catabolic agents such as corticosteroids, oral testosterone or derivatives, or oral beta agonists
• Use of an experimental drug in an FSHD clinical trial within the past 30 days
• Pregnant or nursing women for women of childbearing age
• Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code